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Abstract 
The ever increasing challenge of pathogenic bacteria becoming resistant to multiple 
antibiotics has spawned the search for new antibacterial drugs and new targets for 
antibacterial drugs. Virulence factors could be such new drug targets. Here I present an 
in vivo model of the infectious disease cholera using the bacteria grazing nematode 
Caenorhabditis elegans. I show that the non-pathogenic (CTX¯) Vibrio cholerae O1 El Tor 
strain 2740-80 is ingested by C. elegans and establishes a lethal infection in the intestinal 
tract of the worm. I found that the virulence of V. cholerae, determined as its ability to 
kill C. elegans, was induced by growth of the bacteria under anaerobic conditions. I 
further wanted to test the effect of small cyclic peptides in preventing the virulence of 
V. cholerae and thereby rescuing C. elegans from infection. The peptides were 
synthesized by using the SICLOPPS (split intein-mediated circular ligation of peptides 
and proteins) technology. This allowed for the synthesis of 21 amino acids long cyclic 
peptides, with a central sequence of six randomized amino acids, intracellular in V. 
cholerae. A library of an estimated 14,000 clones was constructed, each clone expressing 
a different peptide. In order to test the individual clones a killing/rescue assay in 
liquid medium was set up in 96-well microtiter plates. This simple system was used to 
screen 350 clones/peptides. None of the clones promoted survival of the worms, but I 
contribute this to the low number of clones tested. Despite the lack of a positive 
outcome, my experiments indicate that this assay could be used to screen for peptides 
that target bacterial virulence. 
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Resumé 
De øgede problemer med antibiotikaresistents blandt pathogene bakterier har 
nødvendiggjort en søgen efter nye antibiotika og nye ’targets’ for antibiotika. Virulens 
faktorer udgør en ny klasse af ’targets’ som først for nylig er begyndt at blive 
udforsket. Jeg beskriver her et in vivo assay for infektionssygdommen kolera, med den 
bakteriegræssende nematode Caenorhabditis elegans. Jeg viser at den ikke-pathogene 
(CTX¯) Vibrio cholerae stamme O1 El Tor 2780-40 bliver indtaget af C. elegans og 
etablerer en dødelig infektion i ormens tarmkanal. Jeg fandt at virulensen af V. cholera, 
bestemt ved dens evne til at inficere og dræbe C. elegans, blev induceret ved vækst af 
bakterien under anaerobe betingelser. Jeg ønskede endvidere at teste små cirkulære 
peptiders potentiale i at hæmme virulensen i V. cholerae og dermed redde C. elegans fra 
infektion. Peptiderne  blev udtrykt ved hjælp af SICLOPPS (split intein-mediated 
circular ligation of peptides and proteins) teknologien. Det tillod synthese af 21 
aminosyrer lange cirkulære peptider, med en seks aminosyrer lang central sekvens af 
tilfældige aminosyrer, intracellulært i V. cholerae. Et bibliotek blev konstrueret 
bestående af anslået 14,000 kloner, der hver udtrykker et individuelt peptid. For at 
teste disse kloner/peptider konstruerede jeg et assay, i flydende medie, i 96-brønds 
mikrotiterplader. Ved hjælp af dette simple assay, screenede jeg 350 kloner/peptider. 
Ingen af de testede kloner undlod at inficere ormene, men jeg tilskriver dette det lave 
antal kloner jeg fik testet. Til trods for det negative udfald mener jeg at dette relativt 
simple assay vil kunne bruges til at finde nye kandidater til stoffer rettet imod bakteriel 
virulens og at cirkulære peptider vil kunne være sådanne. 
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Abbreviations and Definitions 
AKI: Medium designed for optimal expression of cholera toxin 
Antibiotic: naturally occurring antibacterial compound 
Bactericidal: causes death to bacteria 
Bacteristatic: inhibits growth of bacteria 
bla: The β-lactamase gene; resistance to penicillin 
cat: The chloramphenicol acetyl transferase gene; resistance to chloramphenicol 
DHF: Dihydrofolate 
DHFR: Dihydrofolate Reductase  
GFP: Green fluorescent Protein 
L1-4: Larval stages 1-4 
LB: Luria-Bertani medium 
LPS: Lipopolysaccharide 
MDR: Multidrug Resistant 
Microbivore: Animal that feeds on microorganisms 
MRSA: Methicillin-Resistant Staphylococcus aureus 
NAG: N-acetylglucosamine  
NAMA: N-acetylmuramic acid 
NGM: Nematode Growth Medium 
PABA: para-aminobenzoic acid 
PBPs: Penicillin-Binding Proteins 
SICLOPPS: Split intein-mediated circular ligation of peptides and proteins 
Suicide Vector: a plasmid that cannot replicate in a particular host 
THF: Tetrahydrofolate 
VPI: V. cholerae Pathogenecity Island 
VSP: Vibrio Seventh Pandemic island 
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Introduction 
The problem of antibiotic resistance among pathogenic bacteria is as old as antibiotics 
themselves. The antibacterial drugs in use today all, with few exceptions, make use of 
targets such as: cell wall synthesis, DNA replication, RNA transcription, protein 
synthesis and folic acid synthesis. Common for all of these drugs is that resistant 
bacteria have emerged only a few years after their introduction into clinical use. 
Sulphonamides were the first large-scale clinically successful antibacterial drugs. They 
were introduced in the mid 1930s and by the end of the 1930s sulphonamide-resistant 
Streptococcus pyogenes had emerged. Penicillin-resistant Staphylococcus aureus were 
detected in hospitals in the 1940s; the same decade that penicillin was introduced 
(Levy and Marshall, 2004). During the 1940s and 1950s these single-drug resistance 
problems were overcome by a wave of novels classes of antibiotics such as: 
cephalosporins, glycopeptides and tetracyclines. In the late 1950s and early 1960s 
multidrug resistant (MDR) strains started to emerge. In Japan strains of Shigella were 
isolated from patients suffering from dysentery. These strains were resistant to several 
drugs, including sulphonamides, streptomycin, chloramphenicol and tetracycline. It 
was discovered that most of the patients carrying MDR Shigella strains also had MDR 
Escherichia coli in their intestines. This indicated for the first time that drug resistance 
genes could be transferred between bacteria, and not only of the same species (Franklin 
et al., 2005). Today MDR strains of Mycobacterium tuberculosis, Enterococcus faecium, 
Klebsiella pneumoniae, Pseudomonas aeruginosa and methicillin-resistant Staphylococcus 
aureus (MRSA) are a common health problem, especially in developing countries. 
These MDR strains make the treatment considerably more costly and sometimes 
unsuccessful (Levy and Marshall, 2004).  
 
The driving force behind the increasing drug resistance is undoubtedly the immense 
amounts of antibacterial drugs used in the prophylaxis and treatment of humans and 
animals worldwide. Efforts clearly have to be taken in order to minimize the 
unnecessary use of antibacterial drugs, in order to control the spread of resistance. 
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However a renewed search for new antibacterial drugs and new targets for drugs is 
also necessary. Despite the obvious need for new and improved treatments, only one 
truly new class of antibacterial drugs, the oxazolidinones, has come into clinical use 
within the last  three decades (Shinabarger et al., 1997). New antibacterial drugs are 
usually discovered by modifying and testing known compounds or by screening new 
compounds for antibacterial effect. This type of primary testing often involves in vitro 
inhibition of a narrow group of organisms considered representative. Even though this 
strategy has yielded many efficient compounds over the years, it will only identify 
compounds that directly affect bacterial growth. It will not reveal compounds that 
make the bacteria non-virulent or more susceptible to host defences. 
 
In vitro and in vivo assays could instead be designed to screen for new classes of targets 
such as virulence factors, which only just recently has begun to be investigated (Hung 
et al., 2005). In this thesis I describe an in vivo assay for peptides inhibiting virulence in 
Vibrio cholerae. The assay uses the bacteria grassing nematode Caenorhabditis elegans as 
an infection model. 
Antibacterial Drugs 
The general strategy when combating bacterial infections is to kill or inhibit the growth 
of the bacteria without harming the patient. In order to achieve this selective toxic 
drugs are used. The antibacterial drugs target essential features in prokaryotic 
organisms that are absent or different in eukaryotes. The vast majority of antibacterial 
drugs inhibit either the bacterial cell wall synthesis or bacterial protein synthesis, but 
other processes are targeted as well. Figure 1 gives an overview of some common 
targets and examples of drug classes and drugs targeting these. 
INHIBITORS OF BACTERIAL CELL WALL SYNTHESIS 
The prime target of most antibacterial drugs is the bacterial cell wall. Practically all 
bacteria have a cell wall, with a few exceptions such as mycoplasmas, whereas 
eukaryotic cells lack this feature. Most eukaryotic animal cells exist in a controlled 
environment with constant temperature and osmolarity. This allows the cells to 
survive  with  only the soft cell membrane as an outer barrier. 
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Figure 1. Different antibacterial drugs and their targets in the prokaryotic cell. THF, 
tetrahydrofolate; DHF, dihydrofolate; PABA, para-aminobenzoic acid. The figure 
was adapted from Alberts, 2008. 
 
Bacteria on the other hand often exist in hostile environments with changing 
temperatures and osmolarity. This means that bacteria need a stronger and more 
protective layer outside the cell membrane. This layer is the cell wall; it protects the cell 
from the environment and preserves the shape of the bacterial cell. The cell wall in 
both Gram-positive and Gram-negative bacteria is made from cross-linked chains of 
alternating units of N-acetylglucosamine and N-acetylmuramic acid, called 
peptidoglucan. The synthesis is outlined in figure 2A. N-acetylmuramic acid (NAMA) 
is formed from N-acetylglucosamine (NAG) by adding lactic acid derived from 
phosphoenolpyruvate. The next step is the addition of three amino acids to the 
carboxylic group of NAMA. Meanwhile two L-alanines are converted to D-alanine by a 
racemase and the two D-alanines are joined by a ligase to form a D-alanyl-D-alanine 
dipeptide. This dipeptide is added to the three amino acid residue to form the 
pentapeptide side chain on the NAMA-pentapeptide. This NAMA-pentapeptide is 
joined to a molecule of NAG. Up until this point the synthesis has taken place in the 
cytosol. The next step is to transport the entire building block across 
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Figure 2A) shows a simplified outline of the synthesis of the peptidoglycan layer. 
NAG, N-acetylglucosamine; NAMA, N-acetylmuramic acid. A few antibacterial 
drugs and their targets are indicated in red. B) Gram-positive bacteria have a thick 
layer of heavily cross-linked peptidoglycan positioned outside the cytoplasmic 
membrane. Teichoic acids and lipoteichoic acids are attached to the peptidoglycan 
and accounts for 30-40% of the cell wall mass. C) Gram-negative bacteria have two 
membranes, with the peptidoglycan layer located in the periplasmic space. The 
peptidoglycan layer is considerably thinner and has less cross-linking than seen in 
Gram-positive bacteria. Lipoproteins link the outer membrane to the peptidoglycan 
layer. Figure A) was adapted from Greenwood, 2007. B) and C) was adapted from 
Alberts, 2008. (Alberts, 2008) 
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the cell membrane via a lipid carrier. Outside the cell membrane the building blocks 
are added to the existing peptidoglycan. The linear peptidoglycan chains are cross 
linked to give the cell wall its strength. The cross-linking (also called transpeptidation) 
takes place between the pentapeptide side chains of the peptidoglycan chains. The 
cross-linking is performed by membrane bound proteins called penicillin-binding 
proteins (PBPs). PBPs are the main target of penicillin and other β-lactams (such as 
cephalosporins). PBPs vary from species to species in number, size and their affinity to 
different β-lactam antibiotics.  
The cell wall of Gram-positive bacteria is thick (about 30 nm) with several layers of 
peptidoglycan (see figure 2B).  The peptidoglycan is heavily cross-linked both within 
and between the layers. Attached to the peptidoglycan are polysugarphosphates 
(teichoic acids), some of these have lipophilic tails buried in the cytoplasmic membrane 
(lipoteichoic acids). Polysaccharides and proteins also occur in the cell wall of Gram-
positive bacteria, attached to the peptidoglycan, giving the bacteria their antigenic 
properties. Gram-negative bacteria have a thinner peptidoglycan layer (about 2 nm) 
that is loosely cross-linked and lacks the polysugarphosphates (see figure 2C). Outside 
the peptidoglycan layer is the 6-10 nm thick outer membrane. This membrane is similar 
to cell membrane, but the outer half of the lipid bilayer consists of lipopolysaccharide 
(LPS) instead of phospholipids. The sugar side chains (the O-antigens) give Gram-
negative bacteria a large part of their antigenic properties. The outer membrane is an 
efficient barrier for many hydrophilic compounds. In order to facilitate the uptake of 
such the outer membrane contains numerous aqueous channels, named porins, which 
allows passage of hydrophilic molecules. The effect of antibacterial drugs against 
Gram-negative bacteria is often dependant of their ability to pass through these 
channels.  
β-Lactam antibiotics  
Penicillins and cephalosporins belong to the class of antibiotics known as β-Lactams, 
because they both contain a β-lactam ring (see figure 3). Different types of Penicillins 
and cephalosporins can be produced by exchanging the side-chains of the molecules. 
This has broadened their spectrum and combated resistance problems. β-Lactams 
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work by interfering with the cross-linking of the peptidoglycan layer. They do this by 
binding to the various PBPs involved biosynthesis of the peptidoglycan layer. They 
gain access to the enzymatic site of the PBPs through their resemblance of the alanyl-
alanine end group, but unlike the D-alanyl-D-alanine is only released slowly thereby 
blocking the site. The number of different PBPs varies between different species of 
bacteria. Escherichia coli has seven of these proteins: 1a, 1b, 2, 3, 4, 5 and 6. Different 
penicillins and cephalosporins exhibit different affinity for the various PBPs. Drugs 
that target PBPs 1a and 1b induces lysis of the cells by preventing the cross-linking 
(and thus strengthening) of the peptidoglycan layer. Drugs targeting PBPs 2 result in 
spherical cells by inhibiting reshaping of the peptidoglycan layer. PBPs 3 is involved in 
septum formation during cell division. If inhibited the cells become long and 
filamented. Most β-Lactams target PBPs 1-3 and induce lysis of growing bacteria, but 
some cephalosporins (such as cephalexin) bind primarily to PBPs 2 and 3 resulting in a 
slower killing (Franklin et al., 2005). 
 
Figure 3. The structure of benzylpenicillin and cephalosporin C. The fused ring 
system which characterizes these two types of β-Lactams is indicated. Semi-
synthetic derivates have been developed in both classes by modifying the indicated 
side-chains.  
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Figure 4. The glycopeptide antibiotic vancomycin and the polypeptide antibiotic 
bacitracin. Because of their large molecular size they are only effective against 
Gram-positive bacteria. 
Glycopeptide antibiotics 
Glycopeptides antibiotics like vancomycin are complex heterocyclic molecules 
consisting of a heptapeptide backbone with sugars attached to the side-chains (see 
figure 4).  They are among the most important drugs against MRSA and other Gram-
positive infections. They are too bulky to pass the outer membrane of Gram-negative 
bacteria. They bind to the D-alanyl-D-alanine groups on the peptidoglycan and prevent 
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both chain elongation and cross-linking. This mechanism of blocking the substrate and 
not the target enzyme is unusual among antibiotics (Franklin et al., 2005). 
Bacitracin 
Bacitracin is a polypeptide drug isolated from Bacillus subtilis strain Tracy-I (for the 
structure see figure 4). Bacitracin inhibits the dephosphorylation of the membrane 
bound lipid-carrier that transfers the peptidoglycan units across the cell membrane. 
Like the glycopeptides, bacitracin is only effective against Gram-positive bacteria 
because of its large molecular size. Like many related cyclic peptides (like gramicidin 
and tyrocidine) it is too toxic for systemic use. It is only used in topical preparation and 
sometimes in intramuscular injections (Franklin et al., 2005). 
Cycloserine 
Cycloserine is a broad-spectrum drug now only used against MDR Mycobacterium 
tuberculosis (see the structure in figure 5). It inhibits the alanine racemase and the D-
alanyl-D-alanine ligase, because of its structural resemblance with D-alanine. This 
inhibition takes place in the cytosol. Cycloserine enters the cells by active transport, 
thereby reaching a higher concentration than in the medium. This improves its efficacy 
considerably (Franklin et al., 2005).    
 
 
Figure 5.  The structure of cycloserine. 
 
INHIBITORS OF BACTERIAL PROTEIN SYNHESIS 
Many clinically important antibacterial drugs inhibit bacterial protein synthesis by 
binding with the prokaryotic 70S ribosome, without affecting the 80S eukaryotic 
ribosome. However the mitochondrial ribosome bares great resemblance to the 
prokaryotic ribosome; probably because mitochondria have derived from endo-
symbiotic bacteria during the course of evolution. This means that a safe inhibitor of 
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bacterial protein synthesis must be able to gain access to bacterial ribosomes, but not 
mitochondrial. Figure 6 gives an overview of the protein synthesis in bacteria. 
 
 
Figure 6. The protein synthesis in prokaryotes: the first step is the formation of an 
initiation complex with mRNA, the 30S subunit and the N-formyl-methionyl 
transfer RNA (fMet-tRNAF). fMet-tRNAF binds the AUG start codon (sometimes 
GUG). The next step is the association of 30S and 50S to form the 70S ribosome with 
the fMet-tRNAF occupying the ‘peptidyl donor’ site (P site). An aminoacyl tRNA 
fitting the second codon enters the ‘acceptor’ site (A site). The enzyme peptidyl 
transferase (a part of the 50S subunit) attaches the formylmethionine to the new 
amino acid with a peptide bond. The mRNA and the ribosome move with respect to 
one another so that the dipeptide is allocated to the P site and the next codon is in 
the A site, ready for the next aminoacyl tRNA. The deacylated tRNAF transfers to the 
‘ejection’ site (E site) and leaves the ribosome. In this example the fourth codon is a 
stop codon. This signals the termination and release of the peptide and the 
disassembly of the ribosome. 
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Streptomycin 
Streptomycin is produced by the actinomycete Streptomyces griseus. It belongs to the 
group of aminoglycoside antibiotics (its structure can be seen in figure 7). The drug 
inhibits the initiation of the protein synthesis by binding to the 30S subunit of the 
assembled 70S ribosome. It also slows down the elongation of already started peptide 
chains and induces ribosomal misreading of the mRNA. It exert its function by 
blocking the A site of the ribosome. Most inhibitors of protein synthesis are 
bacteristatic and bacteria can resume growth if the drugs are removed. Streptomycin is 
unusual in this respect by being bactericidal. This effect is contributed to its ability to 
induce ribosomal misreading; the resulting miscoded proteins are not able to perform 
their normal role in the cell and eventually the cell dies (Franklin et al., 2005).   
 
 
Figure 7. The structure of four inhibitors of the bacterial protein synthesis. 
Tetracyclines 
Tetracycline is isolated from Streptomyces aureofaciens. Like streptomycin they bind to 
the 30S subunit at the A site, inhibiting the binding of aminoacyl-tRNAs. Unlike most 
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other antibacterial drugs, tetracyclines also inhibit the 80S human ribosome. It is 
however much more effective against bacteria since many of these actively pumps the 
drug into the cytosol. Many forms of broad-spectrum tetracyclines have been designed 
by adding functional groups to the ring structure (Franklin et al., 2005). 
Chloramphenicol 
Chloramphenicol was originally isolated from Streptomyces venequelae, but is now being 
produced synthetically. It is effective against a broad spectrum of Gram-negative and 
Gram-positive bacteria. It binds to the A site of the 50S subunit and thereby inhibits the 
action of the peptidyl transferase. Chloramphenicol has no effect on the 80S human 
ribosome, but can induce bone marrow suppression in susceptible individuals; 
probably by affecting the mitochondrial ribosomes. This have restricted its clinical use; 
it is only used as a reserve drug for use in life-threatening infections (Franklin et al., 
2005; Greenwood, 2007). 
Oxazolidinones 
The oxazolidinones are synthetic antibacterial drugs. As mentioned earlier they are the 
only true new class of antibacterial drugs to be discovered in 30 years. They exhibit 
bacteristatic effect by binding the 23s RNA of the 50S subunit, preventing it from 
forming a functional 70S ribosome. Oxazolidinones such as linezolid (see figure 7) are 
effective against Gram-positive bacteria such as MRSA, but are less effective against 
Gram-negative bacteria(Franklin et al., 2005). 
 
INHIBITORS OF NUCLEIC ACID BIOSYNTHESIS 
The synthesis of DNA and the different types of RNA is essential to the growth of 
bacteria. Antibacterial drugs can either interfere with the synthesis of the building 
blocks of DNA and RNA, or they can target the enzymes involved in DNA or RNA 
synthesis. 
Sulphonamides antibacterials 
Several bacteria have a nutritional requirement for p-aminobenzoic acid, which is 
essential for bacterial folate synthesis. These bacteria synthesize folic acid and cannot 
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take up preformed folic acid from the environment (see figure 8). Humans in contrast 
cannot synthesize folic acid but must acquire it from the diet. Because of their 
structural resemblance with PABA, sulphonamides inhibit the enzyme dihydro-
pteroate synthase in a competitive manner. The bacteristatic effect takes place as the 
pools of purines and pyrimidines are depleted   
 
 
Figure 8. The sites of action of a sulphonamides and trimethoprim in the folic acid 
pathway. 
Trimethoprim 
Trimethoprim is an inhibitor of dihydrofolate reductase (DHFR). DHFR is also present 
in human, but the drug is highly selective against the bacterial enzyme. Trimethoprim 
is often used in combination with sulphonamides. 
Quinolones 
Quinolones such as nalidixic acid and the newer ciproflaxin (see figure 9) are among 
the very few inhibitors of the DNA replication. More exactly they target the bacterial 
topoisomerases. The DNA of a bacterial cell is supercoiled in order to minimize its size. 
The enzyme that introduces negative supercoiling is named type II topoisomerase or 
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DNA gyrase. The supercoiling process involves the introduction of double stranded 
nicks in the DNA; the quinolones inhibits the religation of the nicks and the 
accumulation of nicks in the genome eventually kills the bacterium. The early 
quinolones such as nalidixic acid were only effective against Gram-negative bacteria, 
but never compounds such as ciprofloxacin are also effective against Gram-positives.  
   
 
Figure 9. Examples of quinolones: nalidixic acid and ciprofloxacin, and the RNA 
polymerase inhibitor rifampicin (or rifampin). 
Rifampicin 
Rifampicin is a broad-spectrum antibiotic produced by Streptomyces mediterranei. It 
inhibits the bacterial RNA polymerase by binding to the β subunit. This sterically 
blocks the path of the growing mRNA chain after two or three nucleotides have been 
added. However if the chain has progressed beyond three nucleotides the process is 
insensitive to rifampicin, and the mRNA will be completely transcribed. Rifampicin is 
one of the most useful drugs against tuberculosis and leprosy. 
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AGENTS TARGETING THE CELL MEMBRANE 
In recent years there has been a growing interest in drugs targeting the bacterial cell 
membrane. Almost all higher organisms express short cationic peptides as part of their 
inate immune system (such as defensins in humans). They are usually short (10-50 
amino acids) with a large proportion (≥30%) of hydrophobic residues. This allows 
them to fold into an amphiphilic structure. This structure enables the to bury 
themselves into the cell membrane with the hydrophobic residues in contact with the 
tails of the phospholipids and positively charged residues in contact with the polar 
heads of the phospholipids. This can lead to disruption of the cell membrane, but the 
drugs can also activate immune cells and activate them against the bacteria or enter the 
bacteria and inhibit internal targets (Hancock and Sahl, 2006). 
 
 
Figure 10. The structure of the cationic peptide antibiotic polymyxin B. 
Polymyxins 
polymyxins are produced by Bacillus polymyxa strains (see figure 10). They are basic 
peptides of about eight amino acids in a cyclic structure (not unlike bacitracin).  They 
target the outer cell membrane of Gram-negative bacteria; they insert themselves in the 
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outer LPS leaf thereby increasing its surface area compared to the inner leaf. When this 
tension is relieved the polymyxins gain access to the periplasmic space and the cell 
membrane. As with bacitracin they are only for topical use, such as ear- or eyedrops, 
due to their systemic toxicity (Franklin et al., 2005; Greenwood, 2007). 
 
Antibacterial Drug resistance 
Bacteria and antibiotic producing microorganisms have existed side by side up 
through the evolution, so it is not surprising that bacteria have evolved defences 
against antibiotics.  
INTRINSIC RESISTANCE 
Some bacteria are naturally resistant to certain antibacterial drugs. Mycoplasmas lack 
the cell wall and are therefore unaffected by β-lactamases and other antibacterial drugs 
targeting the cell wall synthesis. The Gram-positive mycobacteria has dense lipid coat 
in the outer layers of the cell wall; this layer resembles the outer membrane of Gram-
negative bacteria and is a barrier against many common antibacterial drugs. 
Mycobacteria also exhibit a very slow growth rate; treatment of infections, such as 
tuberculosis and leprosy, therefore requires several months of continuous treatment.  
The complex outer membrane of Gram-negative bacteria is more rigid than the plasma 
membrane and less diffusible by many antibiotics. The drugs therefore rely on the 
porin channels for their entry into the periplasmic space. The opportunistic pathogen 
Pseudomonas aeruginosa is characterized by having very restricted porin channels 
making it resistant to many antibacterials (Franklin et al., 2005).  
 
Many bacteria (including P. aeruginosa) can in some situations form biofilm. It is 
believed that cells living in biofilm change their growth dynamic, rendering them 
unsusceptible to many antibacterial drugs. Intrinsic resistance is fortunately often 
predictable and infections can be treated by choosing the right type of drug. A bigger 
challenge is posed by the much more unpredictable phenomenon of acquired 
resistance. 
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ACQUIRED RESISTANCE  
The emergence of resistant bacteria among species that would normally be considered 
susceptible has made it clear that bacteria can acquire resistance. Many different 
biological mechanisms behind acquired resistance have been characterized. Figure 11 
illustrates some of the most common mechanisms. 
 
 
Figure 11. A variety of resistance mechanisms have evolved among bacteria. I: 
genetic mutations can alter the binding site of the antibiotic and prevent binding. II: 
enzymes can inactivate the drugs, such as β-lactamases that destroy penicillins and 
cephalosporins. III: Efflux pumps can actively pump the antibiotic out of the cell. 
IV: modifying enzymes can inactivate the antibiotics by adding new functional 
groups. Figure adapted from Levy and Marshall, 2004. (Levy and Marshall, 2004) 
Modification of drug targets 
Resistance to several drugs can arise from mutations affecting the drug target. Analysis 
of streptomycin resistant Mycobacterium tuberculosis has shown that about 70% carry 
point-mutations in the rpsL gene, which encode the S12 protein of the 30S ribosomal 
subunit, causing resistance to streptomycin. The mutations caused lysine-43 or lysine-
88 of the protein to be replaced by arginine residues and thereby loss of binding of 
streptomycin to the 30S subunit (Franklin et al., 2005). 
Resistance to rifampicin has been shown to be caused by point-mutation in the rpoB 
gene, which encode the β subunit of the RNA polymerase, preventing binding of 
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rifampicin to the polymerase. Mutations conferring resistance to rifampicin usually 
causes slower growth of the bacteria, but naturally slow-growing bacteria such as 
Mycobacterium tuberculosis does not seem to suffer from this (Franklin et al., 2005). 
Enzymatic inactivation of drugs 
The destruction of penicillin and cephalosporins by β-lactamases is the most wide-
spread types of bacterial resistance. The β-lactamases cleave the β-lactam ring of 
penicillin and cephalosporin yielding the inactive derivates penicilloic acid and 
cephalosporanoic acid. In order to combat resistance new types of penicillin and 
cephalosporins were developed, but β-lactamases targeting the new drugs have 
emerged just as rapid. So far more than 340 different β-lactamases have been 
identified. The β-lactamase genes are usually carried on plasmid and clinically isolated 
bacteria often express several different β-lactamases (Franklin et al., 2005). 
Resistance to chloramphenicol is primarily due to the enzyme chloramphenicol acetyl 
transferase (CAT). The enzyme acetylates the primary hydroxyl group of the drug 
thereby inactivating it. Genes encoding CAT are wide-spread among both Gram-
positives and Gram-negatives, and are often located on plasmids. Streptomycin and 
other aminoglycosides are often inactivated by phosphorylation, adenylation or N-
acetylation. More than 50 types of these enzymes are known (Franklin et al., 2005). 
Drug efflux pumps 
Resistance towards tetracyclines are in most cases caused by tetracycline-specific efflux 
pumps, usually encoded by plasmid-borne genes. More than 25 different tetracycline 
efflux pump genes have been identified. The efflux pumps are membrane-spanning 
multimer proteins; they actively pump tetracyclines out of the cytoplasm in exchange 
of proton (Franklin et al., 2005). Other efflux pumps exist that target other antibacterial 
drugs, such as chloramphenicol and quinolones. 
Other mechanisms of resistance 
Resistance to tetracycline is usually caused by efflux pumps, but can also be caused by 
so-called ribosomal protection. The resistance is mediated by ribosomal protection 
proteins; these proteins are believed to bind to the 30S subunit and induce a 
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conformational change in the ribosome – leading to displacement of tetracycline 
(Franklin et al., 2005). 
Vancomycin resistant Enterococcus faecalis strains have become a growing problem in 
hospitals in many parts of the world. The resistance is encoded by the plasmid-borne 
vanA gene cluster. These gene products change the D-alanyl-D-alanine terminal ends of 
the pentapeptide side chains of the peptidoglycan to a D-alanyl-D-lactate. Vancomycin 
has a dramatically lower affinity for the D-alanyl-D-lactate than for the D-alanyl-D-
alanine and the D-alanyl-D-lactate can readily take part in the cross-linking of the 
peptidoglycan. It is feared that the vanA cluster eventually will be transferred to MRSA 
strains rendering them untreatable with vancomycin, since conjugative transfer of 
DNA between Enterococcus faecalis and Staphylococcus aureus has been demonstrated 
under laboratory conditions. However most clinically isolated vancomycin-resistant 
MRSA strains do not carry the vanA locus, instead they are protected from the drug by 
an unusually thick cell wall. It is believed that the drug gets ‘trapped’ in the 
peptidoglycan and never reaches site of synthesis of the peptidoglycan. 
GENETICS OF ANTIBACTERIAL DRUG RESISTANCE 
We saw in the previous section that some of the resistance mechanisms arise from 
mutations in chromosomal genes, such as resistance to streptomycin and rifampicin. 
This type of resistance can arise in pure cultures and resistant mutants can easily be 
selected by growing the bacteria in the presence of the drug. However many types of 
resistance to clinically important drugs can clearly be transferred between bacteria of 
different genera. It is generally believed that many of the genes encoding drug-
resistance arose from antibiotic-producing bacteria themselves. Antibiotic-producing 
bacteria such as the streptomycetes carry them in order to protect themselves from 
their own antibiotics (Benveniste and Davies, 1973; Hopwood, 2007). It is conceivable 
that these genes are being transferred among bacteria. Figure 12 illustrates some of the 
mechanisms by which this transfer can take place. 
Transduction 
Transduction is the transfer of genetic information between bacteria via 
bacteriophages. There are two distinct types of transduction: 
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Generalized transduction takes place during the lytic phase. The phage enzymes that 
package the newly synthesized phage genomes into the phage heads, sometimes by 
accident package a piece of chromosomal or plasmid DNA. This DNA may carry drug-
resistance determinants which will be transferred to a new bacterium by the phage. 
The DNA needs to be incorporated into the chromosome or a plasmid in the new cell 
in order to ‘survive’. 
In specialized transduction the error takes place between the lysogenic and the lytic 
cycle of a temperate phage. When entering into the lytic cycle the phage will excise 
itself from the host genome. This excision process is not always precise and sometimes 
part of the bacterial chromosome flanking the insertion site will be excised along with 
the phage DNA. This DNA will then be transferred to a new bacterium as in 
generalized transduction. Bacteriophages are very species specific, so this type of 
transfer will only take place between closely related bacteria. 
 
Figure 12. Drug resistance genes can be transferred between bacteria by a variety of 
mechanisms. By bacteriophages in a process called transduction; by conjugative 
plasmids, called conjugation and by ‘naked’ DNA, called transformation. Often the 
resistance genes are carried on transposons, easing the insertion into plasmid or 
chromosomal DNA of the recipient. Figure adapted from Levy and Marshall, 2004. 
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Conjugation 
Multiple drug-resistance genes are often carried on so-called R-plasmids. Apart from 
the drug-resistance genes these plasmids often carry genes that mediate conjugative 
transfer of the plasmid in a process similar to the F-plasmid. These transfer-genes 
encode specialized surface structures called ‘sex pili’, similar to those of the F-plasmid. 
A cell with sex pili (the donor) will attach itself to a cell without (the recipient) and the 
cells will be pulled close together. A protein-pore will form between the two 
cytoplasms and the R-plasmid will attach to the pore at a region called the oriT (origin 
of transfer). A single-stranded nick will be introduced at the oriT and the strand will be 
transferred in the 5’ to 3’ direction through the pore into the recipient. The single 
strands in both donor and recipient will be turned into double-stranded DNA by the 
DNA polymerase III.  
It is believed that most R-plasmid encode a repressor of sex pili, as this repressor 
accumulates pilus-formation will cease. This means that transfer of the R-plasmid only 
is possible shortly after it is received (or if repression fails). As a consequence of this is 
that R-plasmids transfers relatively slow (Franklin et al., 2005). 
Transformation 
Most bacteria can under certain conditions take up foreign DNA from the environment 
and incorporate it into their genome. The bacteria must be so-called competent; in this 
state they express proteins that will bind ‘naked’ double-stranded DNA and facilitate 
its uptake. This ‘naked’ DNA could stem from dead and lysed drug-resistant bacteria 
and thereby confer resistance to the recipient. 
Transposons and integrons 
Transduction and transformation requires that the foreign DNA sequences are 
incorporated into the genome of the recipient; either unto the chromosome or a 
plasmid. This could be accomplished by homologous recombination if the foreign 
DNA and the recipients DNA contained homologous sequences. However since drug-
resistance are transferred readily between different genera of bacteria, this is unlikely 
to be the only process. It has become clear that many drug-resistance genes are carried 
on DNA elements called transposons. Transposons can insert themselves into 
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sequences with limited homology. The excision from one piece of DNA and insertion 
into another is performed by enzymes called transposases, encoded by genes carried 
on the transposons themselves. The transposase enzyme recognizes insertion 
sequences (IS elements) at the ends of the transposon. These sequences appear in either 
direct or inverted order at each end. Transposons carry a variety of genes between 
these insertion sequences, often coding for drug-resistance. In some transposons these 
genes are arranged in structures called integrons. Integrons have conserved sequences 
on either side of the inserted genes; the sequences are recognized by integrase enzymes 
and allows for insertion of new genes into the integron (Franklin et al., 2005). 
The above mentioned mechanisms accounts for the remarkable ability of bacteria to 
exchange genetic information such as drug-resistance genes. 
         
Vibrio cholerae 
The gram-negative bacteria Vibrio cholerae is the causative agent of the diarrhoeal 
disease cholera. The bacteria lives in coastal water and has been endemic to southern 
Asia for more than 1000 years, but have also caused seven pandemics over the last 200 
years.  V. cholerae is classified by the O-antigen of the outer polysaccharide layer. More 
than 140 different of these serogroups have been classified, but only two are known to 
have caused pandemic cholera (serogroups O1 and O139). The serotype O1 can be 
subdivided into two biotypes: Classical and El Tor, based on a series of biochemical 
tests. The likely evolution of the pandemic strains of V. cholerae can be seen in figure 13. 
The difference between a pathogenic strains and non-pathogenic strains are 
determined by a small number of genes. The genes that enable a strain to infect and 
cause disease are called virulence genes and the proteins they encode are called 
virulence factors. Many of the virulence genes in V. cholerae are located in so-called 
pathogenecity islands (PAIs). In V. cholerae these are called ‘V. cholerae Pathogenecity 
Islands’ (VPI-I and VPI-II) and ‘Vibrio Seventh Pandemic islands’ (VSP-I and VSP-II). 
These PAIs have been identified by analysis of the G+C content along the genome. The 
PAIs usually have a lower G+C content than the surrounding DNA. This indicates that 
these sequences have been acquired by horizontal gene-transfer, by mechanisms 
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similar to those whereby drug-resistance genes are being exchanged. Analysis of the 
flanking regions indicate that transduction by temperate bacteriophages are a likely 
source (Dziejman et al., 2002; Karaolis et al., 1998). In order to cause cholera the strain 
must carry the temperate phage CTXφ, encoding the cholera toxin (CT).  
 
 
Figure 13. Model for the evolution of the pathogenic strains of Vibrio cholerae. An 
ancient progenitor cell acquired at some point the pathogenecity islands VPI-1, VPI-
2 and the metabolic pathway for synthesis of the O1 surface antigen. Genes in VPI-1 
encodes the toxin co-regulated pili (TCP); these pili are the attachment site for the 
CTX phage. The phage encodes the cholera toxin (CT); there are subtle differences 
between the CTX phages of the Classical and El Tor biotypes. El Tor has also 
acquired the pathogenecity islands VSP-I and VSP-II (Dziejman et al., 2002). The 
Classical O1 strain was responsible for the first six pandemics since 1817; El Tor 
emerged as the cause of the 7th pandemic (1961-1970s). At some point before 1991 an 
El Tor strain acquired the pathway for the O139 antigen. This strain is causing the 
current 8th pandemic. The figure was adapted from Alberts, 2008.         
 
Infection by pathogenic V. cholerae involves most of the steps that characterizes 
pathogenic bacteria: 1. It maintain a reservoir where it lives before and after infection. 
2. Enters the host. 3. Adhere to and colonize the host. 4. Multiply inside the host. 5. 
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Damage the host. 6. Leave the host and returns to the reservoir or enters a new host. 
Figure 14 illustrates these steps for V. cholerae.  
 
 
Figure 14. Vibrio cholerae persist in the environment often in biofilm attached to 
biotic or abiotic surfaces. The bacteria usually enter the host via polluted water. 
They pass the stomach acid and enter the small intestine. When they reach the upper 
small intestine the bacteria penetrates the mucus layer; they collect at the mucosa 
between the vili and attaches to the epithelial cells. Cholera toxin (CT) is exported 
from the bacterium by a type II secretion system. Outside the bacteria the CT binds 
to the epithelial cell surface receptor GM1; the toxin is routed through the Golgi 
apparatus into the endoplasmatic reticulum and ends up in the cytoplasm. Here it 
ADP-ribosylates a adenylate cyclase, leading to production of cyclic AMP (cAMP), 
which activates protein kinase A. Protein kinase A (PKA) then phosphorylates the 
cystic fibrosis transmembrane regulator (CFTR), leading to chloride secretion. This 
gives rise to sodium loss and thus water secretion. Upwards of 20 litre of water can 
be lost per day (Sanchez and Holmgren, 2008). The watery diarrhoea (named rice–
water stool) contains high-virulent V. cholerae, allowing further spread of the 
disease. Without treatment >50% of cholera patients die, with rehydration-treatment 
the mortality is reduced to ~1%.  
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The two best studied virulence factors of V. cholerae are the toxin co-regulated pili 
(TCP) and the cholera toxin (CT). TCP is a type IV pilus that is required for intestinal 
colonization (Rhine and Taylor, 1994); they cause the bacteria to aggregate in the crypts 
of the small intestine, but are probably not involved in adhesion to the epithelial cell. 
The TCP are also the attachment site for the CTXφ phage. The phage expresses the CT 
from the ctxAB genes. The CT consists of one A subunit and five B subunits; the B 
subunits are responsible for the binding to the GM1 receptor on the epithelial cells, and 
the transport over the Golgi apparatus to the endoplasmatic reticulum. Hereafter the A 
subunit is released into the cytosol, where it performs its toxic role - see figure 14 
(Vanden Broeck et al., 2007). Even though the genes for TCP formation (tcpA-F) are 
located in the VPI-1 pathogenecity island, and the CT genes (ctxAB) are located on the 
CTXφ phage they are both under control of the transcriptional activator ToxT (located 
in VPI-1). Figure 15 gives an overview of this regulation, called the ToxR regulon. 
 
 
Figure 15. Environmental signals such as low cell density induces synthesis of small 
RNAs (through luxO – not depicted). These small RNAs cause instability of the 
hapR mRNA. Absence of HapR repressor allows transcription of aphA. The AphAB 
complex activates the transcription of tcpPH. TcpPH together with ToxSR activate 
transcription of toxT. The ToxT dimer binds to the toxboxes in front of ctxAB and 
tcpA-F, and stimulates production of CT and TCP (Matson et al., 2007; Sanchez and 
Holmgren, 2008). Figure adapted from Matson et al., 2007. 
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VIRSTATIN 
Virstatin is an example of a drug capable of inhibiting the virulence of pathogenic 
bacteria. It inhibits the expression of TCP and CT in V. cholerae by inhibiting the 
dimerization of ToxT. (Hung et al., 2005; Shakhnovich et al., 2007). See also figure 16. 
Hung et al. constructed a V. cholerae strain that carried a chromosomally located 
tetracycline-resistance gene under control of the cholera toxin promoter. This strain 
was screened for tetracycline sensitivity (i.e. inhibition of the cholera toxin promoter) 
when grown in the presence of different small-molecule drugs. Virstatin was shown to 
inhibit the production of CT and TCP, without affecting the growth rate, of wild-type 
V. cholerae strains. They also showed that virstatin inhibited the ability of V. cholerae to 
colonize the small intestine of infant mice. They tested the ability of a wild-type V. 
cholerae to colonize the small intestine, with and without virstatin. In the presence of 
virstatin the number of V. cholerae recovered from the mice intestine was 0.01% of that 
recovered from untreated mice.    
 
 
Figure 16. The small bioactive molecule virstatin (4-[N-(1,8-napthalimide)]-n-butyric 
acid) prevents ToxT from forming the active dimer, thereby inhibiting transcription 
of both cholera toxin (CT) and toxin co-regulated pili (TCP). 
 
Cyclic peptide drugs 
In the case of virstatin, Hung et al. screened a commercially available library of 50,000 
small molecules. Another, less expensive, approach is to create a library of V. cholerae 
expressing small cyclic peptides. Such peptides could conceivably act in a manner 
similar to that of virstatin, and interfere with the expression of virulence factors. The 
SICLOPPS (Split intein-mediated circular ligation of peptides and proteins) system can 
be used to generate libraries of cyclic peptides in V. cholerae. An intein is a segment of a 
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protein that is able to splice itself out and rejoin the flanking segments (called exteins) 
with a peptide bond. These types of cis-splicing intein-containing proteins are 
transcribed from a single gene. In the case of split inteins, two genes are involved. The 
SICLOPPS system uses the DnaE split intein from the cyanobacterium Synechocystis sp 
PCC6803. DnaE is the catalytic subunit alpha of DNA polymerase III; it is encoded by 
two separate genes, dnaE-n and dnaE-c. The dnaE-n product consists of a 774 amino 
acids (aa) N-extein region followed by a 123-aa intein region (IN), and the dnaE-c 
product consists of a 36-aa intein region (IC) followed by a  423-aa C-extein region (Wu 
et al., 1998). During trans-splicing the two extein regions are joined together to form the 
complete DnaE protein. In SICLOPPS the two intein regions are rearranged to form a 
cis-intein: IC:target peptide:IN (Evans et al., 2000; Scott et al., 1999). This will result in the 
target peptide being released from the inteins and cyclized (see figure 17).  
 
Figure 17. The SICLOPPS mechanism. The two intein regions folds to form the 
active intein. The cystein at the IN:target peptide junction undergoes an N-to-S acyl 
shift to form a thioester. The thioester undergoes transesterfication, by the serine at 
the IC:target peptide junction, to form the lariat intermediate. The asparagines side-
chain cyclization liberates the cyclic peptide as a lactone. An O-to-N acyl shift 
generates the thermodynamically favoured lactam product. Figure adapted from 
Tavassoli and Benkovic, 2007. (Tavassoli and Benkovic, 2007) 
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A wide range of cyclic peptides or proteins can be expressed by the SICLOPPS system. 
Scott et al. showed that the E. coli enzyme dihydrofolate reductase (DHFR) could be 
expressed and the cyclic DHFR was shown to be more resistant to proteolysis than the  
native linear protein (Scott et al., 1999). It is conceivable that small cyclic peptides 
would also be more resistant to cellular catabolism, than similar linear peptides. Since 
the splicing is only dependant on the chemistry of the inteins and do not require the 
aid of proteases, the system can be carried on a plasmid vector and be utilized in a 
variety of hosts. I will use the SICLOPPS system to generate a library of random cyclic 
peptides, expressed internally in V. cholerae, in order to identify inhibitors of virulence.  
 
In vivo models of cholera 
V. cholerae expresses a number of virulence factors that enables it to colonize a human 
host and induce disease. In vitro models are not likely to replicate the condition inside a 
human host. Therefore in vivo models, that replicate the human disease as closely as 
possible, are essential in order to investigate the effect of drugs against virulence 
factors. Animal models such as infant mice have been used as a cholera infection model 
for more than twenty years. Most adult mammals (except humans) are not colonized 
by V. cholerae. Infant (suckling) mice however are colonized in a fashion which mimic 
that of humans (Klose, 2000). This model has been useful in identifying potential 
virulence factors, but it is less suited for high throughput screening of compound 
libraries. Mammalian models have the disadvantages of long reproductive cycles, 
difficult handling and high cost; not to mention the ethical considerations.    
During the past ten years Caenorhabditis elegans has emerged as a useful infection 
model for several pathogenic bacteria and fungi. 
CAENORHABDITIS ELEGANS 
C. elegans is a small free-living nematode that lives in soil, where it feed on 
microorganisms. There are two sexes, male and hermaphrodite. Hermaphrodites 
produce both eggs and sperm and are capable of self-fertilization as well as fertilization 
by a male. Males produce only sperm and must mate with a hermaphrodite in order to 
reproduce. When self-fertilizing the hermaphrodite will produce approximately 300 
 40
progeny; when fertilized by a male, the male sperm will outcompete the 
hermaphrodites own sperm and the ~1000 progeny produced, will be the result of 
cross-fertilization (Hope, 1999).  
C. elegans life-cycle 
Under laboratory conditions the growth of C. elegans is rapid. It will develop from 
fertilized egg to an adult capable of egg-laying in just three days at room-temperature. 
The hermaphrodite gonads first produce germ cells which differentiate as sperm 
(approximately 300 sperm cells are produced) before switching completely to egg 
production. The sperm cells are stored in the two spermathecas, where they will 
fertilize the passing eggs (see figure 18). 
 
 
Figure 18. Anatomical features of Caenorhabditis elegans. The picture is of an adult 
hermaphrodite C. elegans sek-1 (strain KU4) mutant. The picture was taken using 
bright field microscopy. C. elegans has a simple body plane consisting in essence of 
two concentric tubes. The outer tube is made up of an outer tough collagenous 
cuticle covering the hypodermis of the worm, under which are muscles and nervous 
system. The inner tube consists of the intestine, which runs from the posterior 
pharynx to the anus of the worm. Separating the tubes is a fluid-filled space, the 
pseudocoelom, which contains the gonad. Drawing adapted from Alberts, 2008. 
 
The eggs hatch as larvae and these will develop to adults through four larval stages (L1 
to L4), separated by moults. During each moult the larvae will synthesize a new outer 
cuticle under the old cuticle, and shed the old one. The worms live for a total of 
approximately two weeks, but they are only fertile for about four days. 
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Development from fertilization to hatching is referred to as embryogenesis; this takes 
about 14 hours (at room-temperature) and generates the first larval stage (L1) which is 
only 250 μm long, but has same general structure as the adult worm. Over the next 50 
hours development will proceed through four moults and end up with an adult worm 
capable of reproduction. Under unfavourable environmental conditions (i.e. starvation) 
L2 larvae can moult into so-called dauer larvae. The cuticle of the dauer larva is 
completely sealed, protecting the larva from the environment. The dauer larva is able 
to live for three to four month without developing further. It will only moult into an L4 
larva if a food source becomes available. 
C. elegans immunity 
As a soil-dwelling organism, grassing on microorganisms’, C. elegans must have an 
innate immune system as protection against infections. The first barrier is the tough 
outer cuticle layer that protects the worm from microbial penetration. A second barrier 
is the pharynx; the pharynx has two bulbs, the terminal bulb act as a grinder, which 
mechanically disrupts the ingested microorganisms so that very few intact 
microorganisms enter the intestinal tract. The few whole microorganismes that do 
enter are prevented from colonizing the worm by peristaltic movements, which serve 
to remove harmful microorganismes from the intestinal tract. C. elegans also possesses 
inducible immune pathways that resemble those of the innate immune in mammals. 
These pathways are believed to control responses such as antimicrobial peptides, 
lysozymes and possibly other defence responses (Sifri et al., 2005). One such pathway is 
a p38-like mitogen-activated protein kinase (MAPK) pathway. Worms with defects in 
this pathway are more susceptible to infection by microorganisms (Kim et al., 2002). 
C. elegans as an infection model 
When grown in the laboratory C. elegans are fed on a food source of the Escherichia coli 
strain OP50. By simply replacing this food source with other bacteria or fungi a large 
number of human pathogens have been shown to kill the worm. This killing has been 
interpreted as a result of a pathogenic process similar to that in humans. It has been 
suggested that virulence of bacteria has developed as a defence against microbivores 
such as C. elegans (Vaitkevicius et al., 2006). When feed on E. coli OP50 C. elegans has a 
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life-span of about two weeks; this is significantly shortened when grown on these 
pathogenic bacteria. The killing process can be divided into slow killing where live 
bacteria (which have passed intact through the pharynx) accumulates in the intestine of 
the worm and over time kills it, and fast killing where the killing is mediated by toxins 
secreted by the bacteria. This simple feeding-based pathogenesity model has made C. 
elegans an attractive model for screening of antimicrobials (Breger et al., 2007; Moy et al., 
2006).  
 
In this thesis I describe such an assay between C. elegans and V. cholerae. For safety 
reasons I used a V. cholerae strain that doesn’t express cholera toxin (the strain is an El 
Tor without the CTXφ phage). In the assay I use a C. elegans sek-1 mutant with a defect 
MAPK pathway. As mentioned earlier this makes the worm more susceptible to many 
pathogens including the V. cholerae that I am using.  
 
The killing/rescue assay 
I have constructed a library of 21 amino acids long cyclic peptides, utilizing the 
SICLOPPS system, in order to determine their effect on V. cholerae virulence. 
Degenerate oligonucleotides encoding these peptides were inserted between the IC and 
IN genes, on the SICLOPPS vector; thereby creating an open reading frame encoding 
the desired fusion protein, under control of an arabinose-inducible promoter (PBAD). 
The peptides contain six random amino acids and are expressed internally in V. 
cholerae where they can potentially interfere with protein-protein or other interaction 
and thereby inhibit virulence. Figure 19 presents an overview of the killing/rescue 
assay with V. cholerae and C. elegans. The killing/rescue assay is fairly simple: virulence 
of V. cholerae is induced by growing the bacteria over night under anaerobic conditions. 
Then the peptides are induced by incubating the bacteria with the arabinose inducer; 
afterwards the worms are added and start to feed on the bacteria. Survival of the 
worms is used as the indicator of inhibition of virulence. The clones must be screened 
individually; therefore the ability to infect and screen in liquid medium makes the 
assay less work-intensive and allows for faster screening.  
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Figure 19. Flow-chart of the procedure for screening small circular peptides, in a 
killing/rescue assay with V. cholerae and C. elegans. Three DNA oligoes were 
annealed to form the insert for the library construction. The upper oligo contains a 
central sequence of six codons, where N represents any of the four DNA bases (A, T, 
G or C) and B represents T, G or C. This allows the NNB to encode all the 20 amino 
acids while avoiding the ochre (UAA) and opal (UGA) stop codons. The insert was 
ligated into the vector in-frame with IC and IN. This allows the fusion protein to be 
expressed from the arabinose promoter (PBAD). Since DNA transforms poorly into V. 
cholerae, the vector was transformed into an E. coli donor and then transferred to V. 
cholerae by conjugation, mediated by the mob region on the vector. Transconjugants 
were selected on minimal media agar plates with chloramphenicol (the donor is 
auxotrophic). Six hundred transconjugants were restreaked to fresh selective plates. 
350 of these were screened individually. Two mL of LB with was inoculated with a 
clone. The cultures were incubated at 37° C over night (~16 hours) without shaking. 
Each culture was spun down and the pellet resuspended in 30 μL of nematode 
growth medium (NGM) with the arabinose inducer, and transferred to a well of a 96-
well microtiter plate. The cultures were incubated 4-6 hours, at 37° C, to allow the 
cyclic peptides to be formed. The 96-well plate was allowed to cool to room 
temperature and ~20 L4 stage C. elegans were transferred to each well. The plate was 
incubated at room temperature and scored for dead worms after 1-2 days.    
Vector
IC
IN
E. coli
V. cholerae
CGATAGTGCAGGT   (NNB)6 GGAGCTTCTA
  TATCACGTCCA        6 CCTCGAAGATGATC
PBAD
ClaI SpeI
cat
mob
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Materials and Methods 
Strains 
The Caenorhabditis elegans strains used in this study were the wild-type strain C. elegans 
Bristol N2 and the mutant strains C. elegans sek-1 (km4) and C. elegans glp-4(bn2); sek-1 
(km4). These strains are called N2, KU4 and AU37 respectively, in the following 
sections. The N2 strain was a gift from Karina Trankjær Simonsen, University of 
Southern Denmark. The KU4 strain was obtained from the Caenorhabditis Genetics 
Center (http://cbs.umn.edu/CGC/) and the AU37 strain was a gift from Jennifer 
Powell at Ausubel lab, Massachusetts General Hospital, Boston, MA. All strains were 
maintained using established procedures as described in ‘Wormbook’ (Stiernagle, 
2006). The bacterial strains of Vibrio cholerae and Escherichia coli used in the experiments 
are listed in table 1. 
Table 1. Bacterial strains.  
Strain Description 
V. cholerae 2740-80 El Tor CTX- SmR  (Almeida et al., 1992) 
V. cholerae 2740-80ΔprtV El Tor CTX- SmR ΔprtV 
V. cholerae 2740-80ΔtcpA El Tor CTX- SmR  ΔtcpA 
E. coli MC1000 F- araD139 Δ(araA-leu)7679 (codB-lac)X74 galE15 galK16 
rpsL150 relA1 thi 
E. coli DH10B F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80dlacZΔM15 ΔlacX74 
deoR, recA1 endA1 araD139 Δ(ara leu) galU galK λ- rpsL 
nupG 
E. coli SM10λpir thi-1 thr leu tonA lacY supE recA::RP4-2-Tc::Mu KmR 
λpir 
E. coli S17-1λpir TpR SmR hsdR-M+ pro recA RP4-2-Tc::Mu-Km::Tn7 λpir 
E. coli DH5αλpir recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 
Δ(lacZYA-argF)U169 φ80dlacZΔM15 λpir 
E. coli OP50 uracil- 
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Expression vectors 
I constructed two different SICLOPPS vectors and a vector for expression of GFP 
(green fluorescent protein). See figure 20 for an overview of their construction; a more 
detailed description is given below. 
Figure 20. The expression vectors used in this study; all the vectors are based on the 
expression vector pBAD18. The mobilization region (mob) was inserted into the ClaI 
site and the partition factor (parB) was inserted between ClaI and NdeI. The two 
newly formed ClaI sites are blocked by methylation; this generates the vector pHJ1. 
Vector pHJ2 was constructed by inserting the chloramphenicol resistance gene cat in 
the AseI site of pHJ1, inside the β-lactamase gene (bla). Vector pHJ3 was generated 
by inserting the GFPmut2 gene between EcoRI and XmaI and the cat gene into the 
AseI site of pHJ1 (the cat gene contains an EcoRI site). The first SICLOPPS vector 
(pHJ4) was constructed by inserting the intein region (IC and IN) between the EcoRI 
and XmaI sites of pHJ1, under control of the arabinose promoter (PBAD). The second 
SICLOPPS vector has the intein region under transcriptional control of a synthetic 
lac-promoter (PA1/O4/O3). This was accomplished by removing the arabinose promoter 
and repressor (located between the BstZ17I and XmaI sites of pHJ2) and inserting a 
BstZ17I and XmaI cut PCR fragment with the lac-promoter, intein region and lac-
repressor. The sequences of the target peptides can be inserted in-frame between IC 
and IN, using the ClaI and SpeI sites.  
PA1/O4/O3
lacI
cat
M13
ColE1
mob
parB
pHJ5
cat
M13
ColE1
parB
mob
IC
IN
araC
pHJ4
ClaI
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ClaI
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araC araC
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araC PBAD
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mob mob
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parB
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ColE1 ColE1 ColE1M13
M13
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Vector pHJ1 
The pBAD18 vector offer extremely tight control of expression of cloned genes 
(Guzman et al., 1995). It was chosen as the ‘backbone’ for my vectors. Since DNA 
transforms poorly into V. cholerae, the vector must be capable of transfer by conjugation 
(mobilizable); this is accomplished by adding the mob region from pBBR1MCS (Kovach 
et al., 1995). The mob region was PCR amplified from pJS14 (a derivative of pBBR1MCS) 
with primers 5’-GATACAATCGATTCATCCCAGGTGGCACTTTTCGGG-3’ and 5’-
GATACAATCGATCGGAGAGCAAGCCCGTAGG-3’ (ClaI sites in red and the 
overlapping GATC methylation site underlined). Vector and insert was restriction cut 
with Bsu15I (an isoschizomer of ClaI) and ligated. The ligated vector was 
electroporated into E. coli DH10B cells. Plasmid DNA was isolated from transformants 
and restriction digested with Bsu15 and NdeI; a transformant yielding a 5334 bp and a 
442 bp fragment was used in the next step. The partitioning factor parB of plasmid R1 
was added to the vector in order to stabilize it in V. cholerae; the parB region was PCR 
amplified from plasmid pBR95 (which carries the parB region) with primers 5’-CCTG-
ATGATCATATGGTGAACGGTCTGAATGAGCG-3’ (NdeI site in red) and 5’-GTCAG-
ATCGATCAAGGAGAAAGGGGCTACCGGCG-3’ (with ClaI sites in red and the 
methylation site underlined). Vector and insert was restriction cut with Bsu15I and 
NdeI and ligated. The ligated vector was electroporated into E. coli DH10B. Plasmid 
DNA was isolated from transformants and restriction digested with Bsu15 and NdeI; a 
construct yielding a single 5859 bp fragment was named pHJ1. The single band 
confirms that both ClaI sites were blocked by methylation. 
 
Vector pHJ2 
The resistance towards ampicillin conveyed by the bla gene was substituted for the 
more reliable cat gene (giving resistance to chloramphenicol). The cat gene was PCR 
amplified from plasmid pBAD33 with primers 5’-GATACAATTAATGTAAGTTGGC-
AGCATCACC-3’ and 5’-GATACAATTAATGTAGCACCAGGCGTTTAAG-3’ (with 
AseI sites in red). Vector pHJ1 and the insert were digested with VspI (an isoschizomer 
of AseI) and ligated. The ligated vector was electroporated into E. coli DH10B. 
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Transformants were tested by colony PCR with the cat primers and plasmid from a 
positive clone was named pHJ2. 
Vector pHJ3 
A vector expressing GFP was constructed in order to visualize bacteria inside C. 
elegans. The optimized GFP mutant named GFPmut2 was used (Cormack et al., 1996). 
The GFPmut2 gene from pGFPmut2 was PCR amplified with primers 5’-GCATG-
GAATTCGAAGGAG-ATATACATATGAG-3’ (EcoRI site in red) and 5’-GCTAC-
CCCGGGCAGTTATTTGT-ATAGTTCATCC-3’ (SmaI site in red). Vector pHJ1 and the 
insert were digested with EcoRI and SmaI and ligated. The ligated vector was electro-
porated into E. coli DH10B. Transformants were tested by streaking on LB plates with 
0,2% arabinose and by colony PCR with the GFPmut2 primers. Plasmid from a positive 
clone was digested with VspI and a VspI cut cat PCR fragment was ligated into the 
vector. The reason for not inserting GFPmut2 directly into pHJ2 was that the cat gene 
has an internal EcoRI site. The ligated vector was electroporated into E. coli DH10B. 
Transformants were tested by streaking on LB plates with 0,2% arabinose and by 
colony PCR with the GFPmut2 primers and the cat primers. Plasmid from a positive 
clone was named pHJ3. 
Vector pHJ4 
This SICLOPPS vector was constructed by PCR amplifying the intein (IC:IN) region of 
another SICLOPPS vector pSC118 with primers 5’-GATACAGAATTCTTAACCATG-
GGAGGATCC-3’ (EcoRI site in red) and 5’-GATACACCCGGGAAGCTTGGCTGCAG-
GTCG (SmaI site in red). Vector pHJ1 and the insert were digested with EcoRI and SmaI 
and ligated. The ligated vector was electroporated into E. coli DH10B. Transformants 
were tested by colony PCR with the intein primers. The cat gene was added as 
described for pHJ3. The final SICLOPPS construct was named pHJ4. 
Vector pHJ5 
A second SICLOPPS vector was constructed with the Intein system under 
transcriptional control of a synthetic lac-promoter (PA1/O4/O3 - this artificial promoter is 
considerably stronger than the wild-type lac-promoter). The lac-promoter, intein and 
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lac-repressor region of pSC118 was PCR amplified with primers 5’-GATACAGT-
ATACTCACTAGACTTTGCTTCGCAAGTATCACGAGGCCCTTTCC-3’ (BstZ17I site 
in red) and 5’-GATACACCCGGGGCCCAGTCTTTCGACTGAGG-3’ (XmaI site in red). 
Vector pHJ2 and the insert were digested with Bst1107I (an isoschizomer of BstZ17I) 
and XmaI, and ligated. The ligated vector was electroporated into E. coli DH10B. 
Transformants were tested by colony PCR with the lac-intein-repressor region primers. 
This construct was named pHJ5. 
Deletion mutants of V. cholerae 2740-80 
I created two deletion mutants of V. cholerae 2740-80 by deleting the reading frame of 
the prtV or the tcpA gene; resulting in V. cholerae 2740-80ΔprtV and V. cholerae 2740-
80ΔtcpA respectively. The mutants were created as described by Skorupski and Taylor 
(Skorupski and Taylor, 1996). Figure 21 gives an overview of the vectors used and their 
construction. 
 
Figure 21. The vectors used for creation of the V. cholerae 2740-80 deletion mutants. 
The vector pHJ6 was created by inserting the rpsL gene from E. coli into the ClaI site 
of pSW23T. The vector pHJ6-ΔprtV was created by inserting the 1072 bp region from 
upstream of the prtV gene from V. cholerae 2740-80 and the 986 bp region from 
downstream of prtV. The vector pHJ6-ΔtcpA was created by inserting the 1053 bp 
region upstream of tcpA and the 1003 bp region downstream of tcpA.     
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Vector pHJ6 
The rpsL gene was PCR amplified from E. coli SM10λpir with the primers: 5’-GATACA-
ATCGATGACGAACTGCTATTATTGCAAG-3’ and 5’-GATACAATCGATCCATTA-
AGCCTTAGGACGC-3’ (ClaI sites in red). Vector pSW23T and the PCR fragment were 
digested with Bsu15I and ligated. The ligated vector was electroporated into E. coli 
DH5αλpir. The vector was control digested with SmaI and a clone yielding an 1896 bp 
and a 646 bp fragment was chosen and named pHJ6. 
 
Vector pHJ6-∆prtV 
A 1072 bp large region just upstream of the prtV gene was PCR amplified from V. 
cholerae 2740-80 with primers: 5’-GATACAGGATCCCATTTTATTTCCTTAATATTT-
CC-3’ (BamHI site in red) and 5’-GATACATCTAGAGTTGACTCGAGTTACCGC-3’ 
(XbaI site in red). A 986 bp region downstream of the prtV was PCR amplified with 
primers 5’-GATACAGAATTCCGTTATATCGCCAGCATG-3’ (with EcoRI site in red) 
and 5’-GATACAGGATCCTTCTTCCTTCTCCTTCCATG-3’ (BamHI site in red). Vector 
pHJ6 and the downstream fragment were digested with EcoRI and BamHI and ligated. 
The resulting vector and the upstream fragment was digested with BamHI and XbaI 
and ligated. The ligated vector was electroporated into E. coli DH5αλpir. The vector 
was verified by PCR with primers: 5’-CCCTGAATTAAAGCCACG-3’ and 5’-CAGTG-
AGCAGCAAACCCA-3’; a vector yielding a 320 bp fragment was named pHJ6-∆prtV. 
 
Vector pHJ6-∆tcpA 
A 1053 bp large region upstream of the tcpA gene was PCR amplified from V. cholerae 
2740-80 with primers: 5’-GATACAGAATTCGGTGGAGTTATGGCCAATGG-3’ (with 
EcoRI site in red) and 5’-GATACAGGATCCGCAATACGCACATTTAACCACAC-3’ 
(BamHI site in red). A 1003 bp region downstream of tcpA was PCR amplified with 
primers: 5’-GATACAGGATCCGAACTGCTCCATTCACAGTAGC-3’ (BamHI site in 
red) and 5’-GATACATCTAGACGCACTGACCACATCTATCTG-3’ (XbaI site in red). 
Vector pHJ6 and the upstream fragment were digested with EcoRI and BamHI and 
ligated. The resulting vector and the downstream fragment were digested with BamHI 
and XbaI and ligated. The ligated vector was electroporated into E. coli DH5αλpir. The 
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vector was verified by PCR with primers: 5’-GGACCAAGCAATGCATTTC-3’ and 5’-
GCACCTTCTTTCACGTTG-3’; a vector yielding a 544 bp fragment was named pHJ6-
∆tcpA. 
Creating the deletion mutation of prtV in V. cholerae 2740-80 
Vector pHJ6-∆prtV was electroporated into E. coli SM10λpir. An over night (ON) 
culture of the donor strain SM10λpir/pHJ6-∆prtV was grown in 10 mL LB with 20 
μg/mL of chloramphenicol at 37° C. The recipient strain V. cholerae 2740-80 was grown 
ON in 10 mL LB at 37° C. 500 μL of each culture was washed twice with 500 μL of LB 
and resuspended in 500 μL of LB. 25 μL of each culture was mixed in a drop on a 0.2 
μM filter placed on a LB agarplate. After 4 hours of mating at 37° C, the filter was 
transferred to a microcentrifuge tube with 1 mL 0.9% NaCl. The tube was vortexed for 
one minute and 100 μL of the supernatant was plated on an ABTG agarplate with 10 
μg/mL of chloramphenicol. The plate was incubated for 3 days at 37° C. 
Transconjugants were restreaked on an LB agarplate and the plate was incubated ON 
at 37° C. A number of colonies from the LB agarplate were pooled and transferred to 10 
mL LB with 2500 μg/mL of streptomycin and incubated ON at 37° C with shaking. An 
inoculation loop of the ON culture was streaked onto an LB agarplate with 1000 
μg/mL of streptomycin and incubated ON at 37° C. Colonies growing on the LB 
agarplate with 1000 μg/mL of streptomycin were picked with a toothpick and serial-
streaked on a LB agarplate with 20 μg/mL of chloramphenicol and a LB agarplate. The 
plates were incubated ON at 37° C. Colonies growing on the LB agarplate but not the 
LB agarplate with chloramphenicol were streaked on an ABTG agarplate and tested by 
colony PCR with external primers: 5’-CCCTGAATTAAAGCCACG-3’ and 5’-CAGTG-
AGCAGCAAACCCA-3’; and with internal primers: 5’-TGCCAACCCAGTTATCCG-3’ 
and 5’-CCACGGCTTTCAGTTCATG-3’. Bacteria growing on minimal medium and 
yielding a 320 bp fragment with external primers and no band with the internal 
primers were considered prtV deletion mutants of V. cholerae 2740-80. 
Creating the deletion mutation of tcpA in V. cholerae 2740-80 
V. cholerae 2740-80ΔtcpA was created using the same procedure. Bacteria growing on 
minimal medium and yielding no band in a colony PCR with primers: 5’-
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GATACAGAATTCGGTGGAGTTATGGCCAATGG-3’ and 5’-GCACCTTCTTTCACG-
TTG-3’ were considered tcpA deletion mutants of V. cholerae 2740-80. 
C. elegans solid medium killing assay 
In order to investigate the ability of V. cholerae 2740-80 to kill C. elegans, an assay was 
set up on solid medium. I tested the three C. elegans strains N2, KU4 and AU37 and two 
different media for growth and virulence-induction of V. cholerae 2740-80: LB (10 g of 
tryptone/5 g of yeast extract/5 g of NaCl per litre) and AKI (0.5% NaCl/0.3% 
NaHCO3/0.4% yeast extract/1.5% Bacto-Peptone). The AKI medium is designed to 
enhance production of CT from V. cholerae (Iwanaga and Yamamoto, 1985). 
Day 1: Gravid adults were harvested from a medium-size (100 mm) freshly starved 
NGM plate by washing with 1 mL M9 buffer and collected in a 2 mL microcentifuge 
tube. Worms were collected by centrifugation (1300 rpm/1 min) and the supernatant 
was removed (except ~100 μL). Embryos were isolated by treatment with 1 mL of 
bleach solution (550 μL H2O/200 μL of household bleach/250 μL 2N NaOH). The tube 
was whirly mixed gently once every minute. Embryos were released after 5-10 minutes 
and collected by centrifugation (1300 rpm/1 min). The supernatant was removed and 
the embryos washed 4 times with 1 mL M9 buffer. Embryos were allowed to hatch 
over night at 15° C in 250 μL M9.  
Day 2: The microcentrifuge tube with hatched L1 larvae was put on ice for 5 min and 
the worms collected by centrifugation (1300 rpm/1 min). The supernatant was 
removed, except ~100 μL; the L1 worms were transferred to two NGM plates seeded 
with E. coli OP50. The plates were incubated at room-temperature. 
Day 3: ON cultures of V. cholerae 2740-80 and E. coli OP50 (positive control) were 
inoculated as follows: 50 mL of LB or AKI in Falcon tubes were inoculated with a 
colony of either V. cholerae 2740-80 or OP50 and incubated at 37° C ON without 
shaking. 10 mL of LB or AKI in test tubes were inoculated with a colony of either V. 
cholerae 2740-80 or OP50 and incubated at 37° C ON with vigorous shaking. 
Day 4: ON cultures of OP50 and V. cholerae 2740-80 were harvested and resuspended in 
100 μL of fresh medium (OD600 ~150) and plated on NGM plates. The plates were 
incubated 4-5 hours at 37° C. The L1 worms from day 2 had developed into 
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synchronized L4/young adults worms. The plates were washed with 1.5 mL M9 and 
the worms collected by centrifugation (1300 rpm/2 min). Washed 3 times with M9 and 
resuspended in ~500 μL M9. The NGM plates with OP50 and V. cholerae 2740-80 were 
allowed to cool to room temperature (~30 min) and seeded with ~30 synchronized 
worms. The plates were incubated at room temperature. 
Day 5 - : The plates were scored for live worms. A worm was considered dead if it 
didn’t respond to being poked at the head or tail with a wormpicker. 
Elucidation of the killing mechanism 
Vector pHJ3 was electroporated into the donor strain SM10λpir. The RP4 region 
inserted on its chromosomal DNA encodes pili and other factors for conjugative 
transfer of mobilizable plasmids, such as pHJ3. ON cultures of SM10λpir/pHJ3 and the 
V. cholerae 2740-80 were grown in LB. 25 μL of each culture was mixed in a drop on a 
0.2 μM filter placed on a LB agarplate. After 4 hours of mating at 37° C, the filter was 
transferred to a microcentrifuge tube with 1 mL 0.9% NaCl. The tube was vortexed for 
one minute and 100 μL of the supernatant was plated on an LB agarplate with 20 
μg/mL of chloramphenicol and 100 μg/mL of streptomycin. The plate was incubated 
ON at 37° C. Transconjugants were restreaked on an LB agarplate with 20 μg/mL of 
chloramphenicol, 100 μg/mL of streptomycin and 0.2% arabinose. Yellow colonies 
were restreaked on an ABTG agarplate with 20 μg/mL of chloramphenicol. 
Transconjugants growing on minimal medium with chloramphenicol were considered 
V. cholerae 2740-80/pHJ3. pHJ3 was also electroporated into OP50 creating a control 
strain 
 
Synchronous KU4 worms were prepared as described above; V. cholerae 2740-80/pHJ3 
and E. coli OP50/phj3 were inoculated to 50 mL of LB with 20 μg/mL of 
chloramphenicol and incubated at 37° C ON anaerobically (i.e. in a closed Falcon tube 
and without shaking). The ON cultures were spun down and resuspended in 100 μL 
LB and plated on NGM agarplates with 0.2% arabinose; incubated and seeded with 
worms as described above. The next day worms were washed of the NGM plates with 
1 mL of M9 buffer, washed 10 times with M9 and transferred to agarose pads on slides 
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and examined on a Leica DM5000B fluorescence microscope equipped with a Leica 
DC480 camera. In order to fixate the worms, the slides were incubated at 65° C for ~5 
minutes; this ‘stuns’ the worms long enough for pictures to be taken. Overlay pictures 
of brightfield and fluorescent pictures were created as described by Keene et al., 2008. 
See figure 22. 
 
Figure 22. In Adobe Photoshop, or an equivalent program, the brightfield picture is 
opened (A) and the fluorescent picture is placed on top of the brightfield picture as a 
new layer (B). The opacity of the top layer is adjusted so that the brightfield picture 
can be seen through the opaque fluorescent picture (C). (Keene et al., 2008). 
Expression of cyclic DnaA1-86 
I wanted to test the ability of the two SICLOPPS vectors (pHJ4 and pHJ5) to express 
cyclic peptides inside V. cholerae 2740-80. For this I inserted amino acids 1-86 of DnaA 
(also called domain I) into the two vectors. This sequence was chosen because 
antibodies against it are available. I amplified the region with colony PCR on E. coli 
MC1000 with primers 5’-GACAATCGATGTGGAGTCCGCCGTGTCACT-3’ (ClaI site 
in red) and 5’-GACAACTAGTCGGTTTGGTGCCGACTTCAA-3’ (SpeI site in red). The 
vectors and the insert were digested with Bsu15I and BcuI (an isoschizomer of SpeI) 
and ligated. The ligated vectors were electroporated into DH10B. Transformants were 
tested by colony PCR with the intein primers (see under ‘Vector pHJ4’). Correct 
constructs were transformed into SM10λpir and mated into V. cholerae 2740-80 as 
described above. Two Erlenmeyer flasks with 25 mL LB with 20 μg/mL of 
chloramphenicol were inoculated with V. cholerae 2740-80/pHJ4-dnaA1-86 and V. 
cholerae 2740-80/pHJ5-dnaA1-86. When growing exponentially two zero-samples where 
drawn and put on ice (labelled ‘0’). The cultures were then induced by adding inducers 
to a final concentration of 0.2% arabinose or 1mM IPTG. After three hours induction a 
A B C
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second pair of samples were taken, called ‘3’ and ‘3*’. The ‘3’ samples were put on ice; 
the ‘3*’ samples were incubated at 37° C ON, without shaking. The samples on ice were 
spun down and the supernatant removed, then stored at -20°. After 18 hours of 
induction a new set of samples were taken (called ‘ON’). All samples was normalized 
to the equivalent of 1 mL OD600= 0.2 of culture. The ‘3*’ and ‘ON’ samples were 
centrifuged and the supernatants removed. All pellets were resuspended in 10 μL 10 
mM Tris, pH 8/10 mM MgCl2 by vortexing. 40 μL of SDS-gel loading buffer was added 
to each tube and the tubes were placed in a heatingblock at 95° C. After 5 minutes 10 
μL of each sample was loaded into the wells of a ‘Criterion Precast gel 10-20%, 1.0 mm’. 
The gel was run for 2 hours at 100 V. The gel was semi-dry blotted to a PVDF 
membrane and the DnaA1-86 peptides detected by immunodetection. 
Construction of the cyclic peptide library 
The library construction is based on the procedure described by Cull and colleagues 
(Cull et al., 1992). 100 pmol of 5’-ACCTGCACTAT-3’, 100 pmol of 5’-CTAGTAGAAGC-
TCC-3’ and 100 pmol of 5’-CGATAGTGCAGGT-(NNB)6-GGAGCTTCTA-3’ were 
annealed in 10 μL  annealing buffer (10 mM Tris-Cl, pH 8,5/100mM NaCl), by heating 
to 95° C for 5 minutes and slowly cooling to room temperature over 3 hours. The 
annealed oligoes were ligated to vector pHJ4 cut with Bsu15I and BcuI in four reactions 
of 50 ng vector; 6.25 ng insert; 5 units of T4 DNA ligase (Fermentas); 40 mM Tris-HCl, 
pH 7.8; 10 mM MgCl2; 10 mM DTT; 0.5 mM ATP, in 50 μL in a thermocycler with the 
following program: 495 cycles of 10° C for 30 sec, 30° C for 30 sec, then hold 4° C. The 
four reactions were heat inactivated at 65° C for 10 minutes; then pooled, ethanol 
precipitated and resuspended in 11 μL EB (10 mM Tris-HCl, pH 8.5). One μL of ligated 
vector was electroporated into DH10B and plated on LB agarplates with 20 μg/mL of 
chloramphenicol in order to determine the number of clones in the library. The 
remaining 2 x 5 μL of ligated vector (called pHJ4-Bib) were electroporated into E. coli 
S17-1 pir. The electroporated cells were incubated in 2 x 1 mL LB at 37° C for two hours 
then pooled and transferred to 10 mL LB with 20 μg/mL of chloramphenicol and 
incubated ON at 37° C, 250 rpm shaking. 500 μL of S17-1 pir/pHJ4-Bib was washed 
twice with 500 μL LB and resuspended in 500 μL LB. 25 μL was mated with 25 μL of V. 
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cholerae 2740-80 on a 0.2 μm filter on a LB agarplate. The mating was allowed to 
proceed over night. The filter was transferred to a microcentrifuge tube with 1 mL 0.9% 
NaCl and vortexed for one minute. 10 μL supernatant + 90 μL 0.9% NaCl was plated on 
four ABTG agarplates with 10 μg/mL of chloramphenicol. The plates were incubated 
at 37° C for two days; 600 transconjugants (V. cholerae 2740-80/pHJ4-bib) were 
restreaked to fresh ABTG agarplates with 10 μg/mL of chloramphenicol. The plates 
were stored at room temperature. In order to determine the number of empty vectors 
in the library I performed colony PCR on 24 randomly picked clones with primers 5’-
TTAACCATGGGAGGATCC-3’ and 5’-AAGCTTGGCTGCAGGTCG-3’. The first 
primer binds in IC region, the second between the ClaI and SpeI sites. Empty vectors 
will generate a 230 bp fragment.     
C. elegans killing/rescue assay 
350 clones of V. cholerae 2740-80/pHJ4-bib were tested in a liquid based killing/rescue 
assay. Synchronized KU4 worms were prepared as described under ‘C. elegans solid 
medium killing assay’. Each of the 350 clones was inoculated into a microcentrifuge 
tube containing 2 mL of LB with 10 μg/mL of chloramphenicol. Positive controls of E. 
coli OP50 and negative controls of V. cholerae 2740-80 were inoculated in 2 mL LB. The 
cultures were incubated ON at 37° C without shaking. All tubes were centrifuged 
7000g/5 min and the supernatant removed. V. cholerae 2740-80/pHJ4-bib clones were 
resuspended in 30 μL liquid NGM with 10 μg/mL of chloramphenicol and 0.02% 
arabinose. The positive and negative controls were resuspended in 30 μL liquid NGM 
with 0.02% arabinose. All samples were transferred to 96-well microtiter plates and 
incubated 4-5 hours at 37° C. The microtiter plates were cooled to room temperature 
and ~30 synchronized KU4 worms were transferred to each well. The plates were 
incubated at room temperature for 1-2 days and scored for dead worms, under a 
dissection microscope.  
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Results 
Deletion mutants of V. cholerae 2740-80 
I created deletion mutants of V. cholerae 2740-80, in an attempt to design an avirulent 
strain, incapable of infecting and killing C. elegans. I chose the two known virulence 
genes prtV and tcpA. The prtV gene (GenBank: EAX59102.1))  has recently been shown 
to be important for the killing of C. elegans (Vaitkevicius et al., 2006). The tcpA gene 
(GenBank: EAX60076) encodes a structural part of the toxin co-regulated pili; the pili 
are required for colonization of the small intestine in humans (Rhine and Taylor, 1994). 
 
I created a plasmid-born “deletion allel” without the gene, by amplifying the regions 
upstream and downstream of the gene and inserting them head-to-tail on the vector 
pHJ6. This allel was then transferred to V. cholerae 2740-80 via homologous allelic 
exchange as described by (Skorupski and Taylor, 1996). The pHJ6 vector is based on 
the pSW23T (Demarre et al., 2005), which carries the R6K gamma origin; this origin 
only allows replication in a host engineered to produce the replication protein π (pir+ 
host). When transferred to a host not producing π (pir- host such as V. cholerae 2740-80) 
the vector will behave as a suicide vector. The vector carries the cat gene conferring 
resistance to chloramphenicol and the wild type rpsL gene from E. coli; this gene 
encodes the ribosomal protein S12 which confers sensitivity to streptomycin in the 
streptomycin resistant V. cholerae 2740-80.  
 
The plasmids were transferred from E. coli SM10λpir to V. cholerae 2740-80 by 
conjugation. Transconjugants with the plasmid successfully inserted on the 
chromosomal DNA (by homologous recombination) were selected on chlor-
amphenicol. These transconjugants were then selected on streptomycin in order to 
isolate bacteria that had excised the plasmid by a second recombination event. Roughly 
22% of these can be expected to have deleted the targeted gene. The deletion mutants 
(V. cholerae 2740-80∆prtV and   V. cholerae 2740-80∆tcpA) were identified by colony PCR 
– see figure 23.  
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Figure 23. A: PCR control of V. cholerae 2740-80ΔprtV. Lane 1 is PCR on V. cholerae 
2740-80 wild type (WT) with two external primers, spanning the prtV gene, yielding 
a 3065 bp fragment. Lane 3 is PCR on V. cholerae 2740-80ΔprtV with the same primers 
yielding a 320 bp fragment. Lane 2 is PCR on the WT with prtV internal primers 
yielding a 807 bp fragment. Lane 4 is PCR on the ΔprtV mutant with internal primers 
indicating that the prtV gene has been succesfully deleted. B: PCR control of V. 
cholerae 2740-80ΔtcpA. Lane 1 is PCR with the primers for the tcpA up stream 
fragment of 1077 bp on the WT. Lane 3 is PCR with the same primers on the ΔtcpA 
mutant. Lane 2 is PCR on the WT with one external primer and one internal primer 
yielding a 1628 bp fragent. This fragment is absent in the ΔtcpA mutant – lane 4. 
Marker 1: ‘Lambda DNA/Eco91I Marker’ from Fermentas. Marker 2: ‘MassRuler Low 
Range DNA Ladder’ from Fermentas.  
 
C. elegans solid medium killing assay 
The first step in designing a killing/rescue assay is to determine if the bacteria of 
choice will infect and kill C. elegans. The virulence of most bacteria is dependant on the 
medium and growth conditions. I tested the three strains of bacteria: V. cholerae 2740-
80, V. cholerae 2740-80∆prtV and V. cholerae 2740-80∆tcpA by comparing them to the 
normal laboratory food source E. coli OP50. The bacteria were grown on two different 
media: the standard Luria-Bertani medium (LB) and the AKI medium which have been 
designed to optimize expression of cholera toxin (CT) and toxin co-regulated pili (TCP) 
(Iwanaga and Yamamoto, 1985). Expression of CT and TCP has been shown to increase 
when grown anaerobically (Iwanaga and Yamamoto, 1985); I therefore grew the 
bacteria under both aerobic and anaerobic conditions. I also tested three different 
strains of C. elegans: the wild-type C. elegans strain N2, C. elegans sek-1 (strain KU4) and 
C. elegans sek-1; glp-4 (strain AU37). The sek-1 gene encodes a mitogen-activated protein 
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(MAP) kinase kinase which has been shown to take part in the innate immune 
response to pathogens. The mutation of this gene render the worm more susceptible to 
pathogenic bacteria (Kim et al., 2002). glp-4 mutant worms have normal morphology 
and produce eggs when growing at 15 °C, but do not develop gonads and are unable to 
produce eggs at 25 °C.  
 
E. coli  OP50
V. cholerae 
2740-80
After 1 day After 2 days After 4 days
V. cholerae 
2740-80 ΔprtV
V. cholerae 
2740-80 ΔtcpA
 
Figure 24. The fate of C. elegans strain KU4 when grown on E. coli OP50, V. cholerae 
2740-80, V. cholerae 2740-80ΔprtV and V. cholerae 2740-80ΔtcpA. Bacteria cultures 
were grown anaerobically and plated as a lawn in the centre of the plates. Then ~30 
L4 stage worms were put on each plate. The arrows indicate live worms. When fed 
on E. coli OP50 the worms grow and propagate; but when fed on the three V. 
cholerae strains the worms don’t survive long enough to propagate. It is also 
apparent that the worms are much smaller when feeding on V. cholerae compared to 
the worms fed on E. coli OP50. Pictures were taken with an Olympus Altra20 camera 
mounted on an Olympus SZX7 stereomicroscope.  
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The presence of progeny makes it more difficult to score the viability of the parents in 
an assay; without the sterility mutant one would have to separate the adults from the 
progeny, if the killing is not rapid enough to prevent the worms from producing 
progeny. 
 
I found that when L4 stage C. elegans sek-1 (strain KU4) were fed on anaerobically 
grown V. cholerae 2740-80 the lifespan of the worms was greatly reduced, compared to 
worms fed on the normal laboratory food source E. coli OP50. The worms growing on 
V. cholerae 2740-80 were also considerably smaller than the worms growing on E. coli 
OP50 and showed decreased locomotion; they also spent more time outside the 
bacterial lawn. There was no difference between the wild type V. cholerae 2740-80 and 
the two deletion mutants (see figure 24). I found that aerobically grown V. cholerae 
2740-80 did not kill the worms as effectively as when grown anaerobically (data not 
shown). V. cholerae 2740-80 showed the same ability in killing C. elegans when 
incubated anaerobically in LB and AKI (data not shown). I also found that the wild-
type C. elegans (strain N2) was not susceptible to killing by V. cholerae 2740-80, before 
reproducing and neither was the double mutant C. elegans sek-1; glp-4 (strain AU37) 
(data not shown). Therefore the KU4 strain was chosen in the subsequent experiments. 
Elucidation of the killing mechanism 
In order to investigate the mode of killing by V. cholerae 2740-80, I constructed two 
strains expressing GFP: E. coli OP50/pHJ3 and V. cholerae 2740-80/pHJ3. The vector 
pHJ3 carries the GFPmut2 gene (Cormack et al., 1996) under control of the arabinose 
promoter. This allowed me visualize the bacteria inside C. elegans. It has been shown 
that GFP protein exported out of the cytosol of E. coli fail to fold up in an active 
conformation (Feilmeier et al., 2000). GFP fluorescence is therefore an excellent way to 
measure live/intact bacteria in the intestine of C. elegans sek-1 (strain KU4). Figure 25 
shows the result of C. elegans sek-1 fed on the two strains. It is obvious that the V. 
cholerae 2740-80 expressing GFP accumulate in the intestine of the worm and distends 
the upper intestinal lumen dramatically and thereby inflicting death. This distension 
was not seen in worms feeding on E. coli OP50 expressing GFP. The large difference in 
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size between worms fed on V. cholerae 2740-80/pHJ3 and E. coli OP50/pHJ3 was partly 
due to the fact that the pictures were taken with one days interval. The pictures of 
worms fed on V. cholerae had to be taken after one day of feeding (the worms simply 
didn’t live much longer) and fluorescent (live) E. coli were simply not present in the 
intestine of the worms until after two days. This is probably due to the fact that young 
worms have an effective grinder that only allows very few intact bacteria into the 
intestine. Live bacteria are therefore only seen in older worms with less efficient 
grinders or if the bacteria are capable of colonizing the intestine of the worm.  
   
 
Figure 25. The images show strain KU4 C. elegans sek-1 nematodes after one day of 
feeding on V. cholerae 2740-80/pHJ3 (A) and after two days of feeding on E. coli 
OP50/pHJ3 (B). Live intact Vibrio bacteria seem to colonize and expand the upper 
intestinal tract of the worms; whereas live intact coli bacteria are present in the 
intestine of the worms but without colonizing them. The large size difference is 
only partly due to the age difference. The worms seem to be arrested in their growth 
when fed on V. cholerae 2740-80.   
Expression of cyclic DnaA1-86 
I wanted to verify that it was possible to express cyclic peptides in V. cholerae using the 
SICLOPPS system (Evans et al., 2000; Scott et al., 1999). The system has been shown to 
work in E. coli and a variety of bacterial hosts, but has to my knowledge never been 
used in V. cholerae. In order to verify that the SICLOPPS system would work in V. 
cholerae and to find the best expression system, I constructed two vectors: one with the 
intein system under control of the arabinose inducible promoter (PBAD) and one with 
the artificial lac-promoter (PA1/O4/O3). In order to test their function I inserted domain I 
of the DnaA protein (DnaA1-86) into the vectors and transferred them to V. cholerae 
A B
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2740-80. The vectors were induced in a growth experiment and the presence of cyclic 
DnaA1-86 was verified on a western blot by immunodetection. See figure 26. The pHJ4 
vector showed the strongest expression and was chosen for the library design. 
 
Figure 26. Immunodetection of DnaA1-86. Expression in both vectors appears to be 
tightly repressed in the absence of the inducers (0h). After induction with either 
arabinose (pHJ4-dnaA1-86) or IPTG (pHJ5-dnaA1-86) cyclic DnaA1-86 seems to be 
expressed and spliced rather quickly; already after three hours has all the fusion 
protein been spliced and no intermediates are visible (3h). The samples 3* and ON 
were induced over night without and with shaking respectively. The arabinose 
inducible vector pHJ4 shows the strongest expression. All samples were normalized 
to be the equivalent of OD600=0.2 - however the strong ‘smearing’ in the 3* and ON 
lanes of pHJ4-dnaA1-86 could be binding of the polyclonal primary antibody to 
proteins other than DnaA; indicating that these lanes contained more sample. The 
‘Pageruler Prestained Proteinladder’ (from Fermentas) is in kDa. DnaA1-86 is ~10 
kDa.    
Construction of the cyclic peptide library 
The design of the cyclic peptide library is shown in figure 19 on page 43. The library 
plasmid pHJ4 (see figure 20 on page 46) is based on the pBAD18 vector (Guzman et al., 
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1995) with the expression of the SICLOPPS system under control of the arabinose  
(araB) promoter. Synthetic oligonucleotides were annealed and inserted into the ClaI 
and SpeI sites located between the two intein regions (IC and IN); resulting in the vector 
pHJ4-Bib. The size of the library was estimated from 1 μL pHJ4-Bib transformed into 
DH10B; I got 173 transformants from a 10x dilution. I therefore estimate that the 
remaining 10 μL has ~17,000 clones. From the colony PCR I estimate that roughly 17% 
of the vectors are empty (4 out of 24 – see figure 27). This leaves a library of an 
estimated 14,000 different clones. The library was eletroporated into E. coli S17-1λpir 
and transferred to V. cholerae 2740-80 by conjugation.  
 
Figure 27. PCR control for empty library vectors. Empty vectors generate a 230 bp 
band. OP50/pHJ4 (A) and V. cholerae 2740-80/pHJ4 (B) were used as positive controls 
and SM10λpir/pHJ4-dnaA1-86 (C) as negative control. 24 random clones were picked 
and screened. The marker is a ‘MassRuler Low Range DNA Ladder’ from Fermentas.  
 
C. elegans killing/rescue assay 
Since every clone in the library had to be screened individually it was important to be 
able to screen in liquid medium in 96-well microtiterplates. I therefore set up the assay 
as described in figure 19 on page 43. The bacteria were grown anaerobically in 2 mL of 
LB over night, spun down and resuspended in 30 μL of NGM medium with the 
arabinose inducer and induced for 4-6 hours at 37° C. The worms can usually get 
enough oxygen when grown in ~75 μL medium in the wells of a 96-well microtiter 
plate without shaking. I chose the lowest practical volume in order to be on the save 
side. The synchronized L4 worms were added to each well with a Gilson P200 pipette. 
A ~12.5 μL drop with ~30 worms was added to each well, but since the worm have a 
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tendency to adhere to the tip of the pipette I sometimes had to add a second drop. 
After adding the worms the plates were incubated ON at room temperature. The 
worms were scored as alive or dead over the following days. 
 
The liquid assay was successful in the sense that it allowed me to infect and screen the 
worms in liquid medium. However it was unsuccessful in the sense that none of the 
350 tested clones were able to rescue C. elegans from death. The worms in the wells 
with V. cholerae 2740-80/pHJ4-Bib died rapidly; after only one day all worms were 
dead. A few clones initially promoted longer viability, but these results were not 
reproducible. Figure 28 shows how the worms appear when they are dead or alive. 
 
 
Figure 28. The pictures show worms from the liquid assay. The worms in picture (A) 
were scored as dead and the worms in picture (B) were scored as alive. The live ones 
are from the positive control feeding on E. coli OP50. 
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Discussion 
The increased problems with resistance among pathogenic bacteria have prompted a 
search for new antibacterial drugs and new targets for drugs. Virulence factors 
represents such a new class of targets that has only recently been exploited (Hung et al., 
2005). In order to find new drugs, targeting virulence factors, there is a need for 
development of simple animal models capable of representing the complex host-
pathogen interactions. The use of the non-mammalian model organism Caenorhabditis 
elegans has been proven successful in screening for antimicrobial compounds. Breger 
and colleagues used a C. elegans infection model to identify chemical compounds 
effective against the pathogenic fungi Candida albicans (Breger et al., 2007). Moy and 
colleagues identified synthetic compounds that promoted survival of C. elegans when 
infected with the human opportunistic pathogen Enterococcus faecalis; many of these 
compounds did not affect survival of the bacteria in in vitro assays, indicating that 
these compounds either target virulence factors or stimulate the host defence (Moy et 
al., 2006). Thomsen and colleagues have recently shown that Listeria monocytogenes 
mutants that exhibited reduced virulence in mammalian models also showed reduced 
ability in killing C. elegans, in contrast to the wild-type strain that readily killed the 
worm (Thomsen et al., 2006). C. elegans lacks an adaptive immune system, but 
possesses an innate immune response consisting of physical barriers and at least six 
signal transduction cascades. These cascades are believed to be activated in response to 
bacterial pathogens and lead to expression of effector molecules enabling the worm to 
combat infections (Gravato-Nobre and Hodgkin, 2005). Since the innate immune 
system of humans play a significant role in the response to bacterial infections 
(Gravato-Nobre and Hodgkin, 2005) the use of simple and cost-efficient model 
organisms such as C. elegans can prove increasingly useful.    
        
In this thesis I have tried to solve two problems. 1) To set up a killing/rescue assay 
between V. cholerae 2740-80 and C. elegans. 2) To create a library of V. cholerae 2740-80 
expressing random cyclic peptides and test if they were able to rescue C. elegans from 
being infected and killed by V. cholerae 2740-80.  
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Vibrio cholerae 2740-80 kills C. elegans sek-1 worms. Vibrio cholerae is the gram-
negative bacterium that is the causative agent for the diarrhoeal disease cholera. I 
wanted to show that the bacterium is also lethal to C. elegans. Vaitkevicius and 
colleagues have recently shown that the pathogenic V. cholerae strain C6706 can kill the 
wild-type C. elegans N2 on agar plates (over a period of 7 days). They also showed that 
neither the cholera toxin nor the toxin co-regulated pili were required for the killing of 
the nematode, by testing ctx and tcpA mutants. They found however that the killing of 
C. elegans was dependant on the protease PrtV (Vaitkevicius et al., 2006).  
 
In my experiments I found that the lifespan of C. elegans was not considerably shorter 
when feeding on V. cholerae 2740-80, than when feeding on the standard laboratory 
food source E. coli OP50. I found however that the immune defective strain C. elegans 
sek-1 was killed by V. cholerae 2740-80 over a period of 1-2 days, when fed on 
anaerobically grown V. cholerae 2740-80. This allowed for a more stringent end-point, 
either the worms multiply or they die, instead of scoring worms every day and draw 
mortality-curves. Surprisingly the temperature-sensitive sterile double mutant C. 
elegans sek-1; glp-4 died considerably slower than C. elegans sek-1. Similar observations 
have been done by other researchers (Breger et al., 2007; Moy et al., 2006). This can 
perhaps be explained by a more efficient peristaltic movement of bacteria through the 
intestine of the worm when no eggs are obstructing the movement, thereby hindering 
the bacteria from establishing an infection. 
 
Consistent with the results of Vaitkevicius and colleagues I found that V. cholerae 2740-
80ΔtcpA killed C. elegans sek-1 as fast as the wild type. However I also found that V. 
cholerae 2740-80ΔprtV was equally able to kill C. elegans sek-1. Perhaps the relatively fast 
killing of C. elegans sek-1 by V. cholerae 2740-80 is less dependent on PrtV than the 
slower killing of C. elegans Bristol N2 by V. cholerae strain C6706.   
 
During the experiments I observed that the worms feeding on V. cholerae 2740-80 were 
smaller and less active than worms growing on E. coli OP50. Similar behaviour have 
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previously been reported when C. elegans  was fed on Listeria monocytogenes (Thomsen 
et al., 2006). 
V. cholerae 2740-80 accumulates within the digestive tract of C. elegans sek-1 and 
kills the worm. It is generally considered that there are two distinct modes of bacteria-
mediated killing of C. elegans: ‘fast killing’ where the killing is achieved by toxins 
secreted by the bacterium killing the nematode within hours of infection; and ‘slow 
killing’ where the bacteria accumulates in the digestive tract of the nematode and 
inflicts killing over several days (Sifri et al., 2005). In agreement with the findings of 
Vaitkevicius et al., I show that the killing of C. elegans by V. cholerae 2740-80 is by ‘slow-
killing’ where the bacteria colonize the intestine of the worm and thereby kills it. When 
fed V. cholerae 2740-80 expressing green fluorescent protein (GFP) a large number of 
intact bacteria would accumulate in the digestive tract, causing distension of the 
intestinal lumen. Such distension was not seen when the worms were fed on E. coli 
OP50 expressing GFP. Similar results have been reported when C. elegans was fed on 
Salmonella enterica and  Listeria monocytogenes (Aballay et al., 2000; Thomsen et al., 2006). 
 
Cyclic peptides targeting virulence factors can be expressed inside V. cholerae 2740-
80. The example of virstatin (Hung et al., 2005) shows that it is possible for small 
molecule drugs to target virulence factors in bacteria. Peptide drugs are generally 
considered to have (when compared to small molecule drugs) high specificity, often 
high activity and low toxicity. However a major drawback is their proteolytic 
sensitivity (Meloen et al., 2004). Scott and colleagues have shown that cyclic DHFR 
produced with the SICLOPPS system exhibited higher thermostability and higher 
resistance to proteolysis, than the native protein (Scott et al., 1999). By expressing cyclic 
dnaA1-86 I was able to prove that the SICLOPPS system can be utilized for expressing 
cyclic peptides in V. cholerae.     
 
V. cholerae 2740-80 can infect and kill C. elegans in liquid medium.  A major draw 
back of the cyclic peptide library approach is that every clone has to be screened 
individually. In order to achieve a high-throughput assay it is of vital importance to be 
able to screen in liquid medium in 96-wells microtiterplates. I showed that it was 
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possible to transfer the assay to liquid media and perform both infection and screening 
at the same time. Such an assay is ideal for screening against compounds that target 
virulence factor and inhibit infection. In pursue of this idea I showed that it is possible 
to express small circular peptides internally in V. cholerae 2740-80; such peptides could 
possibly act in a manner similar to that of virstatin and interrupt protein-protein 
interactions necessary for infection. I created a library of V. cholerae 2740-80 expressing 
random cyclic peptides and screened 350 of these in my model. However I did not 
encounter any candidates that prevented killing of the nematodes. This was probably 
due to the low number of colonies screened. 
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